**2023 Grand Rounds - The Evolution of Pharmacotherapy for Pediatric Obesity - Kemper Healthy Lifestyles**

|  |  |
| --- | --- |
| **When:** 11/9/2023 8:00:00 AM - 11/9/2023 9:00:00 AM | **Activity ID: 5829** |
| **Location:** Adele Hall - Auditorium (West Lobby) |
| **Faculty:**

|  |
| --- |
| Daniel S. Hsia, MD |
| Associate Professor |
| Pennington Biomedical Research Center |
|  |

 |
| **Event Description:** [Click here to join the presentation from your laptop or computer.](https://cmkc.tv/3tHadZO) Local and national leaders present pediatric topics in their area of specialty during this weekly series.  |

**Objectives:**

At the conclusion of this activity, the participant will be able to:

1 Summarize current guidelines on using pharmacotherapy for pediatric obesity.

2 Describe the currently approved pharmacotherapy for pediatric obesity.

3 Discuss future research and pharmacotherapy for pediatric obesity.

**Accreditation:**

**Continuing Medical Education (CME)**

Children's Mercy Hospital is accredited by the Missouri State Medical Association to provide continuing medical education for physicians.

Children's Mercy Hospital designates this Live Activity for a maxiumum of 1.00 *AMA PRA Category 1 Credit(s)™.* Physicians should claim only the credit commensurate with the extent of their participation in the activity.





**Dietician**

This program has been approved for Dietician Continuing Education credit by the KDHE, Kansas Sponsorship #D1273, for 1.00 clock hour(s).

**Radiology**

This activity has been approved by ASRT for 1.00 Category A CE credits.

**Other Healthcare Professionals**

Other healthcare professionals who participate in this activity may submit their attendance certificate to their appropriate accrediting organizations or state boards for consideration of credit. Participants are responsible for determining whether this activity meets the requirements for acceptable continuing education.

**Disclosures:**

The planners and faculty of this series have disclosed the following financial relationship(s) with ineligible companies/commercial interests:

|  |  |  |
| --- | --- | --- |
| **Name of individual** | **Individual's role in activity** | **Nature of Relationship(s) / Name of Ineligible Company(s)** |
| Amy L Hill, MBA | Other Planning Committee Member | Nothing to disclose - 06/20/2023 |
| Julia R Broussard, MD | Other Planning Committee Member | Nothing to disclose - 10/30/2023 |
| Jose Cocjin, MD, Physician | Other Planning Committee Member | Nothing to disclose - 01/11/2023 |
| Shayla Sullivant, MD | Other Planning Committee Member | Nothing to disclose - 07/14/2023 |
| Susan B Hathaway, PhD | Other Planning Committee Member | Nothing to disclose - 10/29/2023 |
| Fadi J Al Muhaisen, MBBS | Course Director | Nothing to disclose - 01/11/2023 |
| Joy L Solano, MD | Other Planning Committee Member | Nothing to disclose - 10/30/2023 |
| Rochelle Harris, PhD, ABPP | Other Planning Committee Member | Nothing to disclose - 10/27/2023 |
| Krishna Dummula, MD, FAAP | Other Planning Committee Member | Nothing to disclose - 01/11/2023 |
| Meena Sreedhara, PhD | Other Planning Committee Member |  |
| Brenda Salley, PhD | Other Planning Committee Member |  |
| Rose A. Mettlen, MSW | Other Planning Committee Member | Nothing to disclose - 10/27/2023 |
| Daniel S. Hsia, MD | Faculty | Independent Contractor (included contracted research)-Novo Nordisk (Any division)|Independent Contractor (included contracted research)-Vivus, Inc.|Independent Contractor (included contracted research)-Moderna, Inc.|Independent Contractor (included contracted research)-Lilly (Any division) - 09/01/2023 |